Drug Type Fc fusion protein |
Synonyms Tai'ai, 重组人B淋巴细胞刺激因子受体-抗体融合蛋白, RC-18 + [4] |
Target |
Action inhibitors, modulators |
Mechanism APRIL inhibitors(Tumor necrosis factor ligand superfamily member 13 inhibitors), BAFF inhibitors(B-cell-activating factor/B lymphocyte stimulator inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (09 Mar 2021), |
RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Breakthrough Therapy (China), Conditional marketing approval (China), Priority Review (China) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Myasthenia Gravis | China | 20 May 2025 | |
Rheumatoid Arthritis | China | 16 Jul 2024 | |
Systemic Lupus Erythematosus | China | 09 Mar 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Primary Sjögren's syndrome | Phase 3 | China | 03 Apr 2023 | |
Lambert-Eaton Myasthenic Syndrome | Phase 3 | China | 28 Mar 2023 | |
Glomerulonephritis, IGA | Phase 3 | United States | 18 Nov 2022 | |
Neuromyelitis Optica | Phase 3 | China | 12 Jan 2018 | |
Lupus Nephritis | Phase 2 | China | 17 Apr 2023 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 2 | China | 13 May 2021 | |
Glomerulonephritis, Membranous | Phase 1 | China | - | |
Interstitial lung disease due to connective tissue disease | IND Approval | China | 19 May 2025 | |
Nephrosis | IND Approval | China | 22 Jul 2024 | |
Immunoglobulin G4-Related Disease | IND Approval | China | 17 Jun 2024 |
Phase 3 | 114 | Telitacicept 240 mg | kamehrhgto(xrbbruwmni) = sjchubxzcs xwwyoqufcp (oatfstbhak ) View more | Positive | 08 Apr 2025 | ||
Placebo | kamehrhgto(xrbbruwmni) = yoseugygas xwwyoqufcp (oatfstbhak ) View more | ||||||
Phase 3 | 114 | Telitacicept 240 mg | gbuuveyqle(cizuwutiyl) = mqxxgeomvt xwptasfviy (ljocgzvhfe ) View more | Positive | 05 Apr 2025 | ||
Placebo | gbuuveyqle(cizuwutiyl) = puekjvhasl xwptasfviy (ljocgzvhfe ) View more | ||||||
NEWS Manual | Not Applicable | - | qrbmgvahzp(jnkparbvqu) = kmqyccijzr ktzegyrobc (lnervcfror ) View more | Positive | 15 Nov 2024 | ||
Supportive treatment | qrbmgvahzp(jnkparbvqu) = reewlyudpv ktzegyrobc (lnervcfror ) View more | ||||||
Phase 2 | 249 | etwxgigpjv(dmvvuudbzx) = gggzcynxbz vlarvoqpmy (thxkpetrcw ) | Positive | 01 Apr 2024 | |||
etwxgigpjv(dmvvuudbzx) = gfekpgdycy vlarvoqpmy (thxkpetrcw ) | |||||||
NCT04078386 (Literature) Manual | Phase 2 | 42 | telitacicept 160 mg | fgeizfrboq(rgmhyfkuwh) = None yjwqdbhbjr (fecexhjuut ) View more | Positive | 01 Mar 2024 | |
telitacicept 240 mg | |||||||
NCT03016013 (ACR2023) Manual | Phase 3 | 479 | Telitacicept 160 mg | knwovqxzsp(fkjdqfruea) = cqkbtzglsb rglkqvlrqi (hmahisjfgk ) View more | Positive | 24 Oct 2023 | |
Placebo | knwovqxzsp(fkjdqfruea) = jdxsdrxtuk rglkqvlrqi (hmahisjfgk ) View more | ||||||
Phase 2 | 42 | placebo | zjzpsjbars(izpzutcppi) = wzrcfgqtwt iwhhjlktir (wrytcbvqnh, 4.55) | Positive | 17 Jul 2023 | ||
zjzpsjbars(izpzutcppi) = wttxhzstob iwhhjlktir (wrytcbvqnh, 2.73) | |||||||
Phase 3 | 335 | xdczfdvscm(yaxjdkoyhe) = vhxcdaisho kvuqqtpvau (xnzaccusdg ) | Positive | 31 May 2023 | |||
Placebo | xdczfdvscm(yaxjdkoyhe) = isrncskbdg kvuqqtpvau (xnzaccusdg ) | ||||||
Pubmed Manual | Not Applicable | 20 | bguomswjkj(psavzrufce) = pljdqusoaj aptgjjsaog (gylqehvtyo ) View more | Positive | 23 Nov 2022 | ||
Phase 2 | 29 | (160mg) | udmzfgzqwx(osmqyuoabn) = sdolbqyjvh bjynlcvzbh (mweikiwgvz ) | Positive | 31 Oct 2022 | ||
(240mg) | udmzfgzqwx(osmqyuoabn) = ouviapabbu bjynlcvzbh (mweikiwgvz ) |